Compass Therapeutics (Nasdaq: CMPX) reported a Q2 2026 net loss of $25.2 million, or $0.13 per basic and diluted share, compared with a $19.9 million loss, or $0.14 per share, a year earlier. Higher research, development, and pre-commercialization spending widened the loss, while $180 million in cash and marketable securities is expected to fund operations into 2028. The main near-term focus is FDA feedback on tovecimig ahead of a potential biologics license application later in 2026.
Core earnings data
The clinical-stage company did not report quarterly revenue, making operating expenses and cash use the central financial measures. Operating expenses increased by approximately $5.9 million to $27.0 million, with higher interest income providing a partial offset at the net-loss level.
R&D expense rose primarily because of an additional $2.6 million of costs related to tovecimig. G&A expense increased due to $1.4 million in pre-commercialization costs and $0.8 million of additional stock-based compensation.
| Metric | Q2 2026 | Q2 2025 | Year-over-year change |
|---|---|---|---|
| R&D expense | $19.6 million | $16.4 million | +19% |
| G&A expense | $7.4 million | $4.7 million | +59% |
| Operating loss | $27.0 million | $21.1 million | Widened approximately 28% |
| Interest income | $1.8 million | $1.2 million | +54% |
| Net loss | $25.2 million | $19.9 million | Widened approximately 27% |
| Basic and diluted loss per share | $0.13 | $0.14 | Narrowed by $0.01 |
| Weighted-average shares | 186.8 million | 138.3 million | +35% |
Pipeline and clinical program progress
Tovecimig remains the most advanced program and the main regulatory catalyst. The final analysis of the COMPANION-002 Phase 2/3 study showed an 18.0% overall response rate, representing 20 of 111 patients in the combination arm, compared with 5.3% for paclitaxel alone. Following the reclassification of one patient as a partial response, the reported p-value improved to 0.0228.
Compass is also advancing three earlier-stage programs, with several trial starts and data releases scheduled for the second half of 2026.
| Program | Current update | Next disclosed milestone |
|---|---|---|
| Tovecimig | Final Phase 2/3 ORR of 18.0% versus 5.3% for paclitaxel alone | FDA feedback in Q3; ESMO presentation in October; potential BLA filing later in 2026 |
| CTX-8371 | Cohort expansions enrolling in triple-negative breast cancer, non-small cell lung cancer, and Hodgkin lymphoma | Expansion data expected in Q4 2026 |
| CTX-10726 | First patients dosed in the Phase 1 dose-escalation study | Initial clinical data expected in Q4 2026 |
| CTX-471 | Phase 2 study planned in patients with NCAM-expressing tumors | Trial initiation expected in Q3 2026 |
Profitability, cash flow, and the balance sheet
Cash and marketable securities totaled approximately $180 million on June 30, 2026, down from $209 million at the end of 2025. During the first six months of 2026, Compass used $32 million in operating activities, partially offset by $3 million provided by financing activities, accounting for the approximately $29 million decline in its cash and securities position.
Management expects the existing capital base to fund operations into 2028. That runway covers the planned regulatory work for tovecimig and the currently disclosed clinical milestones across the other three programs, although it does not remove the longer-term financing needs associated with drug development and potential commercialization.
A higher share count narrowed the per-share loss
The improvement in loss per share did not reflect better underlying profitability. Net loss widened by approximately 27%, but the weighted-average share count increased by about 35% to 186.8 million shares. Spreading the larger loss across more shares caused the reported per-share loss to narrow from $0.14 to $0.13.
Management commentary
Management characterized the tovecimig data as increasingly consistent as the company prepares to engage with the FDA. Feedback from that interaction will influence the regulatory path and preparations for a potential BLA filing later in 2026.
Across the broader pipeline, management highlighted active CTX-8371 cohort expansions, enrollment in the first CTX-10726 clinical study, and the planned start of the CTX-471 Phase 2 trial. These programs are expected to produce several updates during the remainder of 2026.
Risks investors need to monitor
- Regulatory uncertainty for tovecimig: The timing and feasibility of a potential BLA filing depend on upcoming FDA feedback. A filing plan does not ensure that the application will proceed on the proposed timeline or receive approval.
- Dependence on clinical results: CTX-8371 and CTX-10726 have Q4 data milestones, while CTX-471 remains scheduled to begin Phase 2 testing. Enrollment, safety, and efficacy results could change development plans.
- Rising development and pre-commercialization costs: Quarterly R&D and G&A expenses both increased, widening the operating loss before any potential product approval or commercialization.
- Ongoing cash requirements: Compass used $32 million in operating cash during the first half. Although management expects runway into 2028, continued trials, regulatory work, and potential commercialization may require additional capital over time.
Summary
Compass Therapeutics’ Q2 2026 results reflected increased investment in tovecimig and preparations for a possible commercial and regulatory transition, alongside continued expansion of the broader pipeline. The wider net loss was partly masked at the per-share level by a larger share count, while the $180 million cash position provides funding into 2028. FDA feedback on tovecimig and the planned second-half clinical updates are the principal next indicators of development progress.
Find out more